Sensorion announced the appointment of Scott D. Myers as Chairman of its Board of Directors and Independent Director. Previously, Mr. Myers served as the Chief Executive Officer and Director of AMAG Pharmaceuticals, Inc, where he led its turnaround and strategic sale to Covis Pharma, in November 2020. He has also served as Chairman of the Board and CEO of Rainier Therapeutics, an oncology biotechnology company focused on late-stage bladder cancer treatment, where he led the sale of Vofatamab to Fusion Pharmaceuticals (FUSN). Scott will succeed Edwin Moses, who is leaving the Board of Sensorion on December 19 in order to focus on his portfolio of other commitments.